1 of 1
Story summary
- The U.S. Food and Drug Administration announced the first recipients of its National Priority Voucher program, with nine treatments receiving expedited reviews in one to two months.
- Launched in June 2023, the program aims to address unmet medical needs and medication affordability by expediting reviews.
- The nine treatments include Regeneron's DB-OTO for deafness and Revolution Medicines' RMC-6236 for pancreatic cancer.
- A second batch of recipients is expected soon.
